How to buy Aeterna Zentaris stock (AEZS)

Aeterna Zentaris is a biotechnology business based in the US. Aeterna Zentaris shares (AEZS) are listed on the NASDAQ and all prices are listed in US Dollars.

Our top picks for where to buy Aeterna Zentaris stock

Buy Aeterna Zentaris stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aeterna Zentaris stock price (NASDAQ: AEZS)

Use our graph to track the performance of AEZS stocks over time.

Aeterna Zentaris shares at a glance

• Key figures

Information last updated 2024-10-06.

52-week range	$3.96 - $11.10
50-day moving average more info button	$5.61
200-day moving average more info button	$5.42
Wall St. target price	$15.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.31

Is it a good time to buy Aeterna Zentaris stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aeterna Zentaris financials

Revenue TTM	$2.4 million
Gross profit TTM	$5.2 million
Return on assets TTM	-29.96%
Return on equity TTM	-81.71%
Profit margin	0%
Book value	$10.68
Market Capitalization more info button	$17.5 million

TTM: trailing 12 months

Aeterna Zentaris share dividends

We're not expecting Aeterna Zentaris to pay a dividend over the next 12 months.

Have Aeterna Zentaris's shares ever split?

Aeterna Zentaris's shares were split on a 0.0236:1 basis on 6 June 2024 . So if you had owned 1 share the day before before the split, the next day you'd have owned 0.0236 shares. This wouldn't directly have changed the overall worth of your Aeterna Zentaris shares – just the quantity. However, indirectly, the new 4137.3% higher share price could have impacted the market appetite for Aeterna Zentaris shares which in turn could have impacted Aeterna Zentaris's share price.

Aeterna Zentaris share price volatility

Over the last 12 months, Aeterna Zentaris's shares have ranged in value from as little as $3.96 up to $11.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeterna Zentaris's is 2.257. This would suggest that Aeterna Zentaris's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aeterna Zentaris overview

Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.

Frequently asked questions

null
What percentage of Aeterna Zentaris is owned by insiders or institutions?
Currently 1.321% of Aeterna Zentaris shares are held by insiders and 5.213% by institutions. When does the fiscal year end for Aeterna Zentaris?
Aeterna Zentaris's fiscal year ends in December. Where is Aeterna Zentaris based?
Aeterna Zentaris's address is: 222 Bay Street, Toronto, Canada, M5K 1E7 What is Aeterna Zentaris's ISIN number?
Aeterna Zentaris's international securities identification number is: CA0079754028 What is Aeterna Zentaris's CUSIP number?
Aeterna Zentaris's Committee on Uniform Securities Identification Procedures number is: 007975105